GlycoMimetics, Inc. is a biotech company with a focus on glycomimetic drugs development to address diseases in the USA, particularly those with unmet medical needs. Their main drug candidate, uproleselan, is used alongside chemotherapy to treat acute myeloid leukemia and is in phase three trials to treat relapsed/refractory AML. They are also developing other programs, including GMI-1359 to target cancers affecting the bone and bone marrow.